Danish Healthtech Stock News

GreenMobility A/S ( CPH:GREENM ) announced strong profits, but the stock was stagnant. Our analysis suggests that...

Last week's profit announcement from Fast Ejendom Danmark A/S ( CPH:FED ) was underwhelming for investors, despite...

Danske Bank shareholders approved all Board proposals at the annual general meeting, including major changes to the Board and capital structure. Martin Blessing was elected Chairman of the Board, marking a leadership change at CPSE:DANSKE. Shareholders backed a reduction in share capital and renewed capital authorisations that reshape the bank’s capital framework. Danske Bank, trading at DKK318.1, has seen a 44.3% return over the past year and a gain over five years of 262.3%. These moves...

AL Sydbank (CPSE:ALSYDB) has come into focus after recent share price pressure, including a 1 day return of 1.1% and an almost 10% decline over the past 3 months, prompting closer attention from investors. See our latest analysis for AL Sydbank. With the share price at DKK505.0, recent momentum has been soft, with a 30 day share price return of a 5.5% decline and a 90 day share price return of a 9.9% decline, set against a 1 year total shareholder return of 20% and a very large 5 year total...

Investors may be wondering whether Novo Nordisk’s current share price reflects its true worth, or if the recent weakness is creating a potential value opportunity. The stock last closed at DKK 240.30, with returns of 1.0% over 7 days, a 1.4% decline over 30 days, a 27.2% decline year to date, and a 48.6% decline over 1 year, while the 5-year return stands at 20.2%. These moves sit against a backdrop of ongoing attention on Novo Nordisk’s role in pharmaceuticals and biotech, including...

SP Group (CPSE:SPG) has wrapped up FY 2025 with fourth quarter revenue of DKK 826.4 million and basic EPS of DKK 7.40, alongside trailing twelve month revenue of DKK 2.95 billion and EPS of DKK 22.21 that reflect a 1.6% earnings increase over the past year. Over recent periods the company has seen quarterly revenue range from DKK 654.8 million to DKK 826.4 million, with basic EPS moving between DKK 4.12 and DKK 7.40. The trailing net profit margin has edged to 9% from 8.9% a year earlier,...

Rockwool (CPSE:ROCK B) has proposed at its upcoming April 15, 2026 AGM to cancel 4,346,560 repurchased class B shares, cutting nominal share capital and amending its Articles of Association. See our latest analysis for Rockwool. That capital reduction proposal comes after a weak stretch for the share price, with a 1 month share price return of a 20.19% decline and a 1 year total shareholder return of a 41.48% decline. This suggests momentum has been soft, even though the 3 year total...

As European markets navigate heightened uncertainty due to geopolitical tensions and soaring energy costs, the pan-European STOXX Europe 600 Index has seen a notable decline of 3.79%. Amidst these challenges, investors may find opportunities in stocks that appear undervalued based on their intrinsic value, offering potential for growth when market conditions stabilize.

FirstFarms FY 2025 Results: Margins Under Pressure As One Off Loss Hits Bottom Line FirstFarms (CPSE:FFARMS) has released its FY 2025 figures with third quarter revenue of DKK 91.7 million, basic EPS of DKK 0.03 on a trailing twelve month basis, and a trailing net profit margin of 0.09% compared with 2.8% a year earlier. Over recent periods, quarterly revenue has moved from DKK 107.4 million in Q3 2024 to DKK 91.7 million in Q3 2025, while basic EPS has swung between a loss of DKK 1.35 in Q1...

Wondering whether Jyske Bank at DKK 862.5 still offers value after a strong run, or if you might be late to the story? The share price has pulled back, with a 1.2% decline over the last week and a 10.1% decline over the last month. The 1 year return is 55.3% and the 5 year return is 215.1%. Recent coverage has focused on Jyske Bank's strong multi year share price performance, with attention on how the current pullback fits within a longer trend of gains such as the 99.1% 3 year return...

A.P. Møller - Mærsk has joined the new Torus Defence Supply Chain alliance to support UK defence logistics and digital military supply chains. The alliance brings together Maersk and other industry partners to work on sovereign defence capability and more resilient logistics for the UK. Separately, Maersk has received approval to amend its bylaws following a capital decrease, reflecting ongoing corporate restructuring. For investors watching CPSE:MAERSK B, these steps add fresh context to a...

Earlier this week, United Biotechnology and Novo Nordisk reported phase 2 data from China showing that UBT251, a once-weekly triple-agonist for GLP-1, GIP and glucagon, reduced HbA1c and body weight more than semaglutide and placebo in people with type 2 diabetes over 24 weeks. This outperformance versus semaglutide adds a potentially important next-generation obesity and diabetes candidate to Novo Nordisk’s pipeline just as competition, pricing pressure and generic semaglutide emerge in key...

Zealand Pharma (CPSE:ZEAL) is setting up a major U.S. research hub in Cambridge, Massachusetts, focused on AI-driven drug discovery and automation. The new site will support work on hybrid therapies, including antibody peptide conjugates and siRNAs, alongside the company’s peptide heritage. The expansion is intended to plug Zealand Pharma directly into the Boston life sciences cluster, with implications for scientific capabilities and hiring. For investors tracking Zealand Pharma at a share...

Lu AF28996 data puts H. Lundbeck (CPSE:HLUN B) pipeline in focus Fresh Phase 1b data for Lundbeck's Lu AF28996 in advanced Parkinson's disease, combined with new insights on multiple system atrophy, has pushed the drugmaker's research pipeline and long term neurology focus back into the spotlight. See our latest analysis for H. Lundbeck. At a share price of DKK37.64, Lundbeck has a 90 day share price return of a 12.47% decline and a 1 year total shareholder return of a 0.50% decline, so...

US FDA issued a formal warning letter to Novo Nordisk (CPSE:NOVO B) over shortcomings in safety monitoring and reporting for Ozempic and Wegovy. The letter cites failures in procedures for capturing and reporting serious and unexpected adverse events in the US market. Regulators are requiring corrective actions and have indicated that continued non compliance could trigger further enforcement. Novo Nordisk, listed as CPSE:NOVO B, is a global pharmaceutical company focused on diabetes and...

Lundbeck’s new clinical data on Lu AF28996 and the amlenetug program at the 2026 AD/PD conference has refocused attention on Genmab (CPSE:GMAB), given its collaboration role in developing amlenetug. See our latest analysis for Genmab. At a share price of DKK1,655.5, Genmab has a 1 day share price return of 1.13%, following a 30 day share price return decline of 10.68% and a 90 day share price return decline of 22.02%. The 1 year total shareholder return of 24.94% contrasts with weaker 3 and 5...

FLSmidth (CPSE:FLS) has drawn fresh attention after announcing a joint venture with local industrial group Texnopark in Uzbekistan, aimed at building a modular service centre for mining customers across Central Asia. See our latest analysis for FLSmidth. While the new Uzbekistan joint venture is grabbing attention, FLSmidth’s 1-day share price return of 3.87% comes after a softer 30-day share price return of 12.49%. This is set against a 1-year total shareholder return of 35.21% and a 5-year...

Tivoli (CPSE:TIV) has released its FY 2025 figures with Q3 total revenue of DKK 440.6 million, Basic EPS of DKK 15.1 and net income of DKK 86.3 million. This sets the tone for how the year is shaping up against a period where trailing 12 month net profit margin sat at 7.5% versus 8.6% the year before. The company has seen quarterly revenue move from DKK 69.9 million and a loss of DKK 99.2 million in Q1 2025 to DKK 375.1 million and net income of DKK 39.6 million in Q2 2025, before reaching...

Why Novozymes’ latest AGM matters for shareholders Novozymes (CPSE:NSIS B) has just wrapped up its Annual General Meeting, where shareholders approved the audited 2025 report and backed an ordinary dividend, putting capital returns and balance sheet choices in focus. See our latest analysis for Novozymes. Despite the AGM’s focus on dividends and capital structure, the share price return has been weaker recently, with a 30 day share price return of 9.66% and a year to date share price return...

Dividend announcement and contract renewal set the tone for ISS (CPSE:ISS) ISS (CPSE:ISS) has attracted fresh attention after announcing an annual dividend of DKK 3.20 per share, alongside renewing and expanding its integrated facilities services partnership with Virgin Media O2 in the UK. See our latest analysis for ISS. At a share price of DKK 222.6, ISS has seen a 3.25% year to date share price return. Its 1 year total shareholder return of 39.06% and 5 year total shareholder return of...

Bylaw changes and capital structure moves grab investor attention Embla Medical hf (CPSE:EMBLA) has drawn fresh interest after its 2026 Annual General Meeting approved share capital reductions, renewed board authorizations for future capital increases, and set out conditions for new share buyback and employee option programs. See our latest analysis for Embla Medical hf. Despite the AGM activity around buybacks and share capital, Embla Medical hf's share price has eased in recent months, with...

If you are wondering whether TORM is priced attractively right now, the key question is how its current share price lines up with the value of its underlying business. The stock last closed at kr.167.55, with returns of 5.6% over 7 days, a 3.4% decline over 30 days, 33.8% year to date and 44.4% over the past year. This raises fair questions about both upside potential and changing risk perceptions. Recent coverage has focused on TORM as a shipping name that remains on many investors'...

If you are wondering whether Ørsted at a last close of 138.0 is a bargain or a value trap, the key is understanding how different valuation methods line up on the stock. The share price has seen mixed performance, with a 7.8% return year to date contrasting with a 24.3% decline over the last year and a 54.7% and 74.6% decline over the past 3 and 5 years respectively. This can change how investors think about both risk and potential upside. Recent coverage around Ørsted has focused on its...

Novo Nordisk (CPSE:NOVO B) is back in focus after the FDA cleared its high dose Wegovy HD in the US, while patent protection for semaglutide in India expires, opening the door to lower cost rivals. See our latest analysis for Novo Nordisk. The FDA approval for Wegovy HD arrives at a time when short term sentiment has cooled, with a 30 day share price return of 23.72% and a 1 year total shareholder return decline of 53.81%, suggesting recent momentum has faded despite longer term gains over 5...